GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in

GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China

ARTEMIS-011, a phase III study conducted for China, met its primary endpoint of progression-free survival in relapsed osteosarcoma